Submitted:
23 October 2024
Posted:
23 October 2024
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Materials and Methods
2.1. Study Design
2.2. Participants
2.3. Salivary Sample Collection
2.4. Salivary Lipid Profile Analysis
2.4.1. Triglycerides
2.4.2. Cholesterol
2.4.3. HDL Levels
2.4.4. LDL Levels
2.4.5. Nitric Oxide
2.5. Statistical Analysis
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Acknowledgments
Conflicts of Interest
References
- Zhou B, Carrillo-Larco RM, Danaei G, Riley LM, Paciorek CJ, Stevens GA, et al. Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. The Lancet 2021;398:957–80. [CrossRef]
- Lin CJ, Lai CK, Kao MC, Wu LT, Lo UG, Lin LC, et al. Impact of cholesterol on disease progression. Biomedicine (Taipei) 2015;5:1–7. [CrossRef]
- Singh, SK. Original Research Relationship between hypertension and serum lipid profile levels. Journal of Advanced Medical and Dental Sciences Research |Vol 2020. [CrossRef]
- Bryan, NS. Nitric oxide deficiency is a primary driver of hypertension. Biochem Pharmacol 2022;206:115325. [CrossRef]
- Nayak SR, Jena I, Mishra PK, Behera S, Ray S. Evaluation of serum nitric oxide in essential hypertension and its correlation with severity of disease. Asian Journal of Pharmaceutical and Clinical Research 2016;9:179–82. [CrossRef]
- Choudhury KN ahar, Mainuddin AKM, Wahiduzzaman M, Islam SM ohammed S. Serum lipid profile and its association with hypertension in Bangladesh. Vasc Health Risk Manag 2014;10:327–32. [CrossRef]
- Kalburgi V, Leburu S, Warad S. Saliva as a surrogate to explore the association between lipid profiles and chronic periodontitis: A case-control study. Dent Res J (Isfahan) 2014;11:619.
- Karjalainen S, Sewón L, Soderling E, Larsson B, Johansson I, Simell O, et al. Salivary Cholesterol of Healthy Adults in Relation to Serum Cholesterol Concentration and Oral Health. Http://DxDoiOrg/101177/00220345970760100401 1997;76:1637–43. [CrossRef]
- Singh V, Patil R, Singh S, Tripathi A, Khanna V, Ali W. Diagnostic significance of serum and salivary lipid levels in oral precancer and oral cancer. Natl J Maxillofac Surg 2021;12:188–92. [CrossRef]
- Al-Rawi, NH. Oxidative stress, antioxidant status and lipid profile in the saliva of type 2 diabetics. Diab Vasc Dis Res 2011;8:22–8. [CrossRef]
- Mani Sundar N, Krishnan V, Krishnaraj S, Hemalatha VT, Alam MN. Comparison of the Salivary and the Serum Nitric Oxide Levels in Chronic and Aggressive Periodontitis: A Biochemical Study. J Clin Diagn Res 2013;7:1223. [CrossRef]
- Sone R, Eda N, Kosaki K, Endo M, Watanabe K. Influence of acute high-intensity exercise on salivary nitric oxide levels. J Oral Sci 2019;61:307–12. [CrossRef]
- Singh D, Mishra M, Gupta Monika, Singh Poonam, Gupta A, Nema R. Nitric Oxide radical scavenging assay of bioactive compounds present in methanol Extract of Centella asiatica. International Journal of Pharmacy and Pharmaceutical Science Research 2012;3:42–4.
- Alshammari SA, Alshammari AS, Alshammari HS, Ahamed SS. Overview of hypertension in Saudi Arabia. Saudi Med J 2023;44:951–64. [CrossRef]
- Yavuz C, Yazici S, Karahan O, Demirtas S, Caliskan A, Guclu O, et al. Serum nitric oxide level could be a predictive biomarker for detection of critical ischaemia duration. Biomarkers 2013;18:116–20. [CrossRef]
- Goswami B, Sarkar S, Sengupta S, Bhattacharjee B. Assessment of serum nitric oxide level and its correlation with anthropometric parameters and lipid profile in diabetic patients: A hospital-based study from Tripura. J Family Med Prim Care 2022;11:5161–5. [CrossRef]
- Kale K, Iyengar A, Kapila R, Chhabra V. Saliva-A Diagnostic Tool in Assessment of Lipid Profile. Scholars Academic Journal of Biosciences (SAJB 2017;5:574–84. [CrossRef]
- Bachtiar EW, Putri AC, Bachtiar BM. Salivary nitric oxide, Simplified Oral Hygiene Index, and salivary flow rate in smokers and non-smokers: a cross-sectional study. F1000Res 2019;8:1744. [CrossRef]
- Ambe K, Watanabe H, Takahashi S, Nakagawa T, Sasaki J. Production and physiological role of NO in the oral cavity. Japanese Dental Science Review 2016;52:14–21. [CrossRef]
- Prasad Nautiyal M, singh Shodi K, Gupta S, Bhaskar N, Jindal M. Estimation of salivary nitrite in patients having hypertension. Indian Journal of Basic and Applied Medical Research 2018:297–306.
- Barbadoro P, Ponzio E, Coccia E, Prospero E, Santarelli A, Rappelli GGL, et al. Association between hypertension, oral microbiome and salivary nitric oxide: A case-control study. Nitric Oxide 2021;106:66–71. [CrossRef]
- Kreisberg RA, Kasim S. Cholesterol metabolism and aging. Am J Med 1987;82:54–60. [CrossRef]
- Spitler KM, Davies BSJ. Aging and plasma triglyceride metabolism. J Lipid Res 2020;61:1161–7. [CrossRef]
- Bahbah EI, Noehammer C, Pulverer W, Jung M, Weinhaeusel A. Salivary biomarkers in cardiovascular disease: An insight into the current evidence. FEBS Journal 2021;288:6392–405. [CrossRef]
| Salivary Test Variables | Control | Test | |||||
|---|---|---|---|---|---|---|---|
| N | Minimum | Maximum | Mean ± SD | Minimum | Maximum | Mean ± SD | |
| TRI (mg/dL) | 40 | 50.0 | 95.0 | 68.85 ± 12.45 | 55 | 180 | 79.4 ± 20.71 |
| CHO (mg/dL) | 40 | 36 | 63 | 52.20 ± 7.19 | 38 | 77 | 55.67 ± 7.14 |
| HDL (mg/dL) | 40 | 9 | 18 | 14.38 ± 2.03 | 9 | 17 | 13.93 ± 2.27 |
| LDL (mg/dL) | 40 | 69 | 99 | 81.85 ± 8.16 | 46 | 116 | 84.80 ± 12.51 |
| NO (µmol/L) | 40 | 148 | 165.8 | 156.27 ± 5.69 | 122 | 140.2 | 127.4 ± 4.46 |
| Salivary parameters | T | Df | p-value |
|---|---|---|---|
| TRI | -2.76 | 78 | 0.007* |
| CHO | -2.17 | 78 | 0.033* |
| HDL | .90 | 78 | 0.371 |
| LDL | -1.22 | 78 | 0.225 |
| NO | 2.47 | 78 | 0.014* |
| Age | TRI | CHO | HDL | LDL | NO | ||
| Age | Pearson Correlation | 1 | .326* | -.184 | -.045 | -.131 | .033 |
| Sig. (2-tailed) | .040* | .255 | .785 | .421 | .840 | ||
| N | 40 | 40 | 40 | 40 | 40 | 40 | |
| TRI | Pearson Correlation | 1 | .008 | -.059 | .006 | -.179 | |
| Sig. (2-tailed) | .959 | .716 | .970 | .269 | |||
| N | 40 | 40 | 40 | 40 | 40 | ||
| CHO | Pearson Correlation | 1 | -.173 | .155 | .083 | ||
| Sig. (2-tailed) | .285 | .339 | .610 | ||||
| N | 40 | 40 | 40 | 40 | |||
| HDL | Pearson Correlation | 1 | -.153 | -.242 | |||
| Sig. (2-tailed) | .344 | .133 | |||||
| N | 40 | 40 | 40 | ||||
| LDL | Pearson Correlation | 1 | .196 | ||||
| Sig. (2-tailed) | .226 | ||||||
| N | 40 | 40 | |||||
| NO | Pearson Correlation | 1 | |||||
| Sig. (2-tailed) | |||||||
| N | 40 | ||||||
| Sum of Squares | df | Mean Square | F | Sig. | LSD Post Hoc at 95% CI | ||
| TRI | Between subgroups | 2802.431 | 2 | 1401.215 | 3.725 | .034* | 1.0-3.0 (p = 0.015*) |
| Within subgroups | 13919.169 | 37 | 376.194 | 1.0-2.0 (p = 0.652) | |||
| Total | 16721.600 | 39 | |||||
| CHO | Between subgroups | 61.007 | 2 | 30.503 | .596 | .556 | - |
| Within subgroups | 1894.544 | 37 | 51.204 | ||||
| Total | 1955.551 | 39 | |||||
| HDL | Between subgroups | .478 | 2 | .239 | .043 | .958 | - |
| Within subgroups | 203.470 | 37 | 5.499 | ||||
| Total | 203.948 | 39 | |||||
| LDL | Between subgroups | 138.188 | 2 | 69.094 | .430 | .653 | - |
| Within subgroups | 5939.052 | 37 | 160.515 | ||||
| Total | 6077.240 | 39 | |||||
| NO | Between subgroups | 41.881 | 2 | 20.940 | .842 | .439 | - |
| Within subgroups | 920.270 | 37 | 24.872 | ||||
| Total | 962.151 | 39 | |||||
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).